Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Addressing the rise of multiple myeloma in Rwanda

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Addressing the rise of multiple myeloma in Rwanda ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Updates from ASCO 2024 in gastrointestinal tumours

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center...

Updates from ASCO 2024 in gastrointestinal tumours ( Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic...

Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany

TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia ( Dr Consuelo Bertossi - University Hospital of Ulm, Ulm, Germany )

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms

Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom

Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms ( Dr Alexandros Rampotas - UCL Cancer Institute, London, United Kingdom )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Ponatinib is better than imatinib for frontline treatment of newly diagnosed...

Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain

Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia ( Prof Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )

Lower levels of inflammatory markers and tumour burden is linked to...

Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France

Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma ( Prof Bertrand Arnulf - Hôpital Saint-Louis, Paris, France )

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157...

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

More from ecancer